<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(10)</volume><submitter>Ma G</submitter><pubmed_abstract>The homeostasis of IgG is maintained by the neonatal Fc receptor, FcRn. Consequently, antagonism of FcRn to reduce endogenous IgG levels is an emerging strategy for treating antibody-mediated autoimmune disorders using either FcRn-specific antibodies or an engineered Fc fragment. For certain FcRn-specific antibodies, this approach has resulted in reductions in the levels of serum albumin, the other major ligand transported by FcRn. Cellular and molecular analyses of a panel of FcRn antagonists have been carried out to elucidate the mechanisms leading to their differential effects on albumin homeostasis. These analyses have identified 2 processes underlying decreases in albumin levels during FcRn blockade: increased degradation of FcRn and competition between antagonist and albumin for FcRn</pubmed_abstract><journal>JCI insight</journal><pagination>e176166</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11141909</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin.</pubmed_title><pmcid>PMC11141909</pmcid><pubmed_authors>Crowley AR</pubmed_authors><pubmed_authors>Hofman E</pubmed_authors><pubmed_authors>Bobkov V</pubmed_authors><pubmed_authors>Ward ES</pubmed_authors><pubmed_authors>de Haard H</pubmed_authors><pubmed_authors>Heyndrickx L</pubmed_authors><pubmed_authors>Rogiers I</pubmed_authors><pubmed_authors>Van Santbergen J</pubmed_authors><pubmed_authors>Ober RJ</pubmed_authors><pubmed_authors>Louagie E</pubmed_authors><pubmed_authors>Parthoens E</pubmed_authors><pubmed_authors>Ulrichts P</pubmed_authors><pubmed_authors>Balbino B</pubmed_authors><pubmed_authors>Ma G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin.</name><description>The homeostasis of IgG is maintained by the neonatal Fc receptor, FcRn. Consequently, antagonism of FcRn to reduce endogenous IgG levels is an emerging strategy for treating antibody-mediated autoimmune disorders using either FcRn-specific antibodies or an engineered Fc fragment. For certain FcRn-specific antibodies, this approach has resulted in reductions in the levels of serum albumin, the other major ligand transported by FcRn. Cellular and molecular analyses of a panel of FcRn antagonists have been carried out to elucidate the mechanisms leading to their differential effects on albumin homeostasis. These analyses have identified 2 processes underlying decreases in albumin levels during FcRn blockade: increased degradation of FcRn and competition between antagonist and albumin for FcRn</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 May</publication><modification>2026-06-02T01:37:30.321Z</modification><creation>2026-04-13T03:12:24.934Z</creation></dates><accession>S-EPMC11141909</accession><cross_references><pubmed>38713534</pubmed><doi>10.1172/jci.insight.176166</doi></cross_references></HashMap>